United States: Cures Are On The House: House Passes 21st Century Cures Act, But Senate Awaits

On July 10, 2015, the House of Representative passed H.R. 6, the 21st Century Cures Act ("Cures Act"), with strong bipartisan support, by a vote of 344-77. This medical innovation reform legislation represents the culmination of more than a year of work by the House Energy & Commerce Committee ("E&C Committee") on the 21st Century Cures Initiative, led by E&C Committee Chairman Fred Upton (R-MI) and Rep. Diana DeGette (D-CO). The Cures Act now moves to the Senate, which has separately been considering medical innovation reforms.

As Ropes & Gray previously reported here and here, the E&C Committee released discussion drafts of the Cures Act in January and April 2015. The April discussion draft had been significantly pared down relative to the January discussion draft, eliminating several potentially controversial proposals, including those relating to drug exclusivity and laboratory-developed tests. Since the release of the April discussion draft, the Cures Act has evolved once again. As enacted by the House, the Cures Act, which currently spans 362 pages, contains various new proposals affecting drug and device manufacturers, as well as substantial changes to a number of proposals found in the April discussion draft. The only significant proposal to be axed from the Cures Act since the April discussion draft related to the sharing of data from NIH-funded research.

The key FDA-related provisions that have been added to or substantially changed in the Cures Act since the April discussion draft are described below. Ropes & Gray has summarized Cures Act provisions related to Medicare and Medicaid, health information/digital health, and regulation of clinical research in separate Alerts.

What Is New?

The Cures Act contains numerous new proposals that were not found in the April discussion draft. The key FDA-related additions include proposals relating to:

  • Communication of Truthful, Non-Misleading Off-Label Information: This provision would require that, within 18 months of enactment, FDA issue a draft guidance facilitating the dissemination of truthful and non misleading scientific information that is not in the approved labeling of drugs and devices. Notably, in June 2014, when the FDA granted a citizen petition submitted by the Medical Information Working Group (as Ropes & Gray previously reported), the FDA announced its own plans to issue guidance "by the end of the calendar year" (i.e., 2014) on distributing scientific and medical information on unapproved new uses and manufacturer discussions regarding scientific information. These guidance documents have yet to be issued. The Cures Act provision would impose a statutory deadline on the FDA's plans.
  • Extended Exclusivity for Previously Approved Drugs and Biologics That Are Approved for a New Rare Disease Indication: This provision would provide an additional six months of exclusivity for already approved drugs and biologics that are approved for a new indication for a rare disease or condition. The additional six months of exclusivity would tack on to the end of any patent protection or exclusivity applicable to the drug or biologic.
  • Reauthorization of Rare Pediatric Disease Priority Review Voucher Program: This provision would reauthorize the FDA's rare pediatric disease priority review voucher program, which encourages the development of drugs to treat rare diseases that primarily affect children by rewarding successful rare disease product applicants with a voucher that can be used to obtain priority review for a subsequent new drug application or biologics license application. (See Ropes & Gray's prior alert for more information.) Without congressional action, the program is scheduled to sunset in March 2016. This provision would extend eligibility in the program to all rare disease product applications submitted through December 31, 2018.
  • Combination Products Review: This provision would require that, within 18 months of enactment, FDA issue a final guidance document describing the responsibilities of each Center regarding the review of combination products.
  • User Fee Exemption From Sequestration: This provision would permanently exempt from sequestration various FDA user fees, including fees for medical devices, prescription drugs, generics drug, biosimilars, animal drugs, and generic animal drugs. The provision would ensure the agency's access to user fees and provide funding for drug and device review and other critical agency functions.

What Else Has Changed?

FDA-related proposals that have substantially changed since the April discussion draft include those relating to:

  • Third-Party Quality System Assessment for Medical Devices: A placeholder in the April discussion draft has been replaced with a provision that would establish a program by which accredited third-parties could review and certify if a device manufacturer's quality system can reasonably assure the safety and effectiveness of devices subject to certain "device related changes." The provision provides that a device-related change covered by such a certification would not be subject to premarket notification, 30-day notice, or Special PMA supplement requirements that might otherwise apply.
  • 510(k)-Exemptions for Certain Class I and II Medical Devices: A placeholder in the April discussion draft related to marketing notifications for class I devices has been replaced with a provision that would require FDA to publish rules identifying any class I and II devices that FDA determines no longer require a 510(k) notification.
  • Expanded Access Programs for Investigational Drugs: A provision calling for drug manufacturers to disclose details on their expanded access programs for any investigational new drug within 60 days after initiating a phase 2 or phase 3 study has been modified to require publication of an expanded access policy at "the first initiation" of a phase 2 or 3 study. In addition, a provision has been added expressly permitting manufacturers to modify publicly available expanded access policies at any time.
  • Reduction of Additional Incentive for Use of New Antimicrobial Drugs: This provision, part of a package of antibiotic-related reforms, decreases the additional payment incentive under Medicare for "DISARM drugs"—approved new antimicrobials intended to treat an infection for which there is an unmet medical need and which is associated with high mortality or patient morbidity—to a set percentage of total hospital payments per fiscal year.

Prospects for the Legislation

Although the Cures Act has cleared the hurdle of the House, the prospects of passage in the Senate remain uncertain. The Senate Health, Education, Labor & Pensions Committee ("HELP Committee") has held numerous hearings over the past several months as it considers its own medical innovation legislation. However, the HELP Committee has not yet released even a discussion draft of its legislation, and one is not expected until at least the end of the Senate recess in August. Following the House's passage of the Cures Act, HELP Committee Chairman Lamar Alexander (R-TN) stated that the Senate's work would continue "on a parallel track . . . to produce a bill that [the Senate] can combine with 21st Century Cures and send to the President's desk."

Prior passage of the Cures Act, the White House, via a statement of administration policy, objected to the bill's use of the government's Strategic Petroleum Reserve to offset the bill's funding increases. The White House would have preferred that the bill directly address sequestration and ensure that FDA has sufficient funding to support all the programs established in the bill. The White House also expressed concern regarding the proposals relating to drug exclusivity and drug manufacturer communications with payors. Whether the Senate's proposed legislation will address the White House's concerns remains to be seen.

Re-authorization of the Prescription Drug User Fee Act ("PDUFA VI") is slated to occur in 2017. Given that PDUFA VI is considered "must-pass" legislation, it is possible that a number of issues under consideration in the Cures Act, particularly those issues lacking consensus, will be deferred until that latter debate.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions